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CHICAGO, ILLC hronic obstructive pulmonary disease(COPD) is a complex systemic disease, thatuntil recently, was underrecognized, underap-
preciated, and poorly understood. Bonet first described
COPD as early as 1679 when he discussed ‘‘voluminous
lungs,’’ and yet it wasn’t until the 1960s that physicians
began to create formalized definitions of the clinical
syndrome they were encountering.1 These initial defini-
tions focused on either clinical characteristics (such as
cough and dyspnea) or anatomic features (such as en-
largement of alveolar spaces) and, in some sense, ne-
glected expanded features that could be useful in
identifying and understanding the disease.1 Still today,
COPD is a defined as ‘‘a common preventable and treat-
able disease, characterized by persistent airflow limita-
tion that is usually progressive and associated with an
enhanced chronic inflammatory response in the airways
and the lung to noxious particles or gases.’’2 This defini-
tion remains broad, describing an ‘‘airflow limitation’’
that, in reality, is caused by distinct features of small-
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Fig 1. Chronic obstructive pulmonary disease (COPD) is a complex
systemic disease. A mix of the patients’ genetic and environmental
milieu, including smoking and nutrition, influences the risk of devel-
oping COPD. In addition, COPD has a variety of clinical presenta-
tions and phenotypes ranging from a disease predominantly of
emphysema to chronic bronchitis to frequent exacerbations. COPD
has been found to have extensive systemic effects and is often linked
to the development of other diseases, including osteoporosis, cardio-
vascular disease, and cancer, and is thought to be a syndrome of sys-
temic inflammation.
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63% and 52%, respectively, whereas death rates result-
ing from COPD increased by 100%.4 Currently, approx-
imately 14million Americans have been diagnosed with
COPD, although it has been estimated that an additional
12 million individuals remain undiagnosed.5 By 2030, it
is estimated that approximately 9 million peoplewill die
annually from COPD.6
COPD is also a source of significant health expendi-
ture and societal costs. Until recently, patients, clini-
cians, and researchers undervalued the overwhelming
impact of this disease on individuals’ quality of life
and society’s economic stability. In 2008, it was esti-
mated that the cost to the United States for COPD and
asthma was approximately $68 billion, including
$14.3 billion in direct costs and $53.7 billion in mortal-
ity costs.5 In a 2001 international study, it was found
that 45.3% of COPD patients younger than 65 years
of age had missed at least 1 day of work within the pre-vious year secondary to COPD. In that same study, pa-
tients with COPD often minimized their own
symptoms; 60.3% of patients who ranked their disease
as mild or moderate reported severe breathlessness.7
In recognition of the increasing prevalence and costs
associated with COPD, during the past decade there has
been great progress in our understanding of the patho-
genesis, manifestations, and clinical outcomes of this
common disease. In this in-depth review issue, we ex-
plore and celebrate the strides made while also identify-
ing areas that require further investigation to expand our
understanding of COPD. Beginning with a discussion of
diet and nutrition, Hanson et al illustrate how vitamins
and micronutrients may modify risk of developing
lung disease that could introduce a true primary preven-
tative strategy for COPD beyond avoidance of cigarette
smoke and environmental pollutants. Aryal et al provide
an update on how COPD risk, manifestations, and out-
comes differ between men and women, thereby illus-
trating the complex nature of COPD and pointing out
opportunities to personalize therapies further. The in-
sightful review of Bon et al focuses us on the complex
nature of COPD and our future ability to personalize
therapy by providing a guide for clinical and transla-
tional investigators on how to address the many attri-
butes that constitute a disease ‘‘phenotype’’ as we
move toward identifying new ways of classifying,
studying, and improving the care of COPD. Last, Bhatt
and Dransfield, through a detailed review on concurrent
cardiovascular disease in COPD, provide an illustrative
example of the impacts comorbid conditions have on
those living with COPD and why both comprehensive
clinical care and clinical investigation in COPD need
to account for the many concurrent conditions that im-
pact patient-centered outcomes and mortality.COPD RISK FACTORS
Although previously understood as a disease almost
exclusively of smokers, we now understand that the
risk of developing COPD is determined by both the ge-
netic and environment milieu of each patient. Alpha-1-
antitrypsin has long been acknowledged as a genetic
cause of COPD, although it affects a relatively small
proportion of patients. Family association studies have
pointed toward other potential genetic causes and,
within the past decade, genomewide association studies
have begun to identify countless single nucleotide poly-
morphisms thought to be associated with the develop-
ment of emphysema and/or COPD.8-11 It is now
understood that numerous environmental factors
impact the development of airway disease. Exposure
to biomass fuel smoke from indoor cooking, for
instance, has been shown to be a large contributor of
Translational Research
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Similarly, growing research has begun to show the
role of diet and nutrition in protecting against the
development of airway disease.
In the first article in this in-depth review of COPD,
Hanson et al discuss the rapidly growing field of diet
and vitamin D, and their associations with lung func-
tion. Their article takes both a micro- and macrolevel
view on the role of nutrients in the development of
lung disease. It describes how vitamins C and E function
as antioxidants in lung parenchyma, as well as how vi-
tamins D and E affect systemic inflammation and lipid
phase oxidation. They walk us through data from obser-
vational studies, longitudinal studies, intervention stud-
ies, and randomized control trials that show numerous
associations between the intake of vitamins A, C, E,
and D, and carotenoids and improved lung function. Al-
though dietary studies in the past have struggled to show
causal relationships, the magnitude of observational re-
search reviewed in this insightful article argues strongly
for the development of future prospective research ini-
tiatives that test the impact of dietary interventions as
a possible means for primary and secondary prevention
of COPD.COPD PHENOTYPES
COPD is a heterogeneous clinical syndrome charac-
terized by a variety of concurrent lung and systemic
manifestations. Although airflow limitation defines
both the presence and stage of disease, this physiologic
measurement is not always well correlated with the
clinical disease characteristics or outcomes for any
given patient. For example, patients with the same de-
gree of airflow limitation, or FEV1, have variable clin-
ical outcomes, such as symptoms, exercise tolerance,
radiographic features, and prevalence of comorbid
conditions.14-16 Although some patients have a
disease predominately of parenchymal destruction
(emphysema), others have more changes to their
small airways (peribronchiolar fibrosis). Although all
patients are at risk of acute exacerbations of disease,
the frequency of exacerbations is not only associated
with the severity or stage of disease. Given the great
clinical variability of this disease, researchers have
begun to define new ways of analyzing and
categorizing patients with COPD into ‘‘clinical
phenotypes,’’ or subgroups of patients with similar
clinical outcomes, to predict prognosis more
accurately and to improve treatment.15,16
At a time when COPD has become increasingly prev-
alent among women, Aryal et al discuss the differences
in prevalence, clinical presentation, morbidity, and mor-
tality, as well as treatment implications for women intheir article on COPD and gender. This review identifies
what could be argued as a separate clinical phenotype
because it shows women are more likely to have a clin-
ically different set of outcomes including symptoms,
comorbidities, and disease course. Although tobacco
use has increased among women during the past few de-
cades, recent studies have found that women may be
more vulnerable to the adverse effects of tobacco and
show more rapid decline after the onset of disease. Us-
ing research from both animal and epidemiologic stud-
ies, this review suggests multiple reasons for the
differences between men and women in COPD risk, in-
cluding anatomic differences, behavioral differences, as
well as biologic and hormonal differences. In addition
to identifying differences in objectively measured risk
and disease manifestations, this review also identifies
biases still held in medicine that impact both the diagno-
sis, treatment, and health care utilization of women with
COPD.
Growing research focuses on defining new clinical
phenotypes within COPD that correspond to clinically
different subgroups of patients with differing clinical
outcomes, such as lung function data, clinical symp-
toms, radiographic evidence of disease, or prognosis.
Reclassification of this complex disease, however,
comes with many challenges of its own. Bon et al focus
on the challenges presented to clinicians and investiga-
tors alike as we attempt to define COPD phenotypes.
They question insightfully whether it is even possible
to place patients into well-defined subgroups of disease
and question whether COPD, instead, represents
a ‘‘continuum of varying penetrance’’ of a number of
different clinical features. They also raise the very im-
portant issue of how best to select specific populations
of COPD patients for clinical studies. For example,
many of our largest studies of COPD have focused
on those with severe airflow limitation, but because
these patients likely have multiple comorbidities, this
may blur boundaries between different phenotypes. In-
stead, we may be better served to focus on mild or sub-
clinical disease in which patients have fewer
confounding factors and the concurrent evolution
from health to disease for the many potential clinical
characteristics of a COPD phenotype could be studied
from their earliest stages of development. A similar
limitation is presented by the many cross-sectional
studies that evaluate patients at only a single time point
in a disease such as COPD that is characterized by in-
termittent exacerbations and progressive decline in
lung function, magnifying the need of the research
community to develop longitudinal cohort studies in in-
dividuals at risk for COPD so the natural history of spe-
cific disease phenotypes can be defined from their
earliest stages.
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Within the past 10 years, clinicians and researchers
have begun to recognize the numerous comorbidities as-
sociated with COPD and the mortality associated with
patients who carry a diagnosis of COPD. Although
COPD is considered the third leading cause of death,
more patients with COPD die from their comorbid
conditions than from COPD or other respiratory
complications. It could be stated that patients do not
always die from but rather with COPD.17-20 Patients
carrying a diagnosis of COPD have higher rates of
hospitalization and mortality for all cardiovascular
end points, including cardiac arrhythmias, angina
pectoris, acute myocardial infarction, congested heart
failure, stroke, and pulmonary embolism.21 The stan-
dard mortality ratio for cardiovascular disease among
patients with COPD on long-term oxygen therapy com-
pared with the general population is significantly ele-
vated at 7.3.22 Patients with COPD have increased
incidence of andmortality frommany other diseases, in-
cluding osteoporosis, lung cancer, diabetes, dyslipide-
mia, anemia, and hypertension, even after adjusting
for smoking, aging, and use of corticosteroids.18,20 To
emphasize the significance of these comorbidities,
some have even suggested adding a diagnosis of
‘‘chronic systemic inflammatory syndrome’’ to all
patients with COPD to reflect more completely the
multifaceted nature of COPD as a systemic disease.23
In the final article of this review, Bhatt and Dransfield
explore the systemic nature of COPD disease as they
present the plethora of research and data regarding con-
current COPD and cardiovascular disease. Stepping
through the diverse interactions between coronary artery
disease, congestive heart failure, cerebrovascular dis-
ease, peripheral vascular disease, and cardiac
arrhythmias, the review analyzes thoughtfully the
epidemiologic and pathophysiologic interrelationship
among these diseases independent of their often com-
mon and shared risk factors. Discussion of multiple pop-
ulation studies showing the link between carotid arterial
intimalmedial thickness and numerous pulmonary func-
tion parameters—including FEV1, diffusing capacity of
carbon monoxide (DLCO), residual volume (RV), and
peak expiratory flow rate—help the reader understand
the relationship between the pathogenesis of atheroscle-
rosis and COPD.Genetic studies illustrate links between
matrix metalloproteinases and glutathione-S-transfer-
ase and the development of emphysema and plaque rup-
ture. In addition, discussion of the epidemiologic
outcomes of patients with both COPD and cardiovascu-
lar disease illustrate the poor prognostic implication of
these overlapping clinical entities and provide opportu-
nities for future research and public health interventions.CONCLUSION
Overall, this in-depth review of COPD steps through
emerging research of risk factors for disease, attempts
and challenges of better describing and categorizing
this disease, as well as the comorbid conditions associ-
ated with COPD as we continue to learn about the com-
plexities of this systemic syndrome. This series not only
celebrates how far we have come since our early de-
scriptions and definitions of disease, but also it high-
lights how much is still unknown, and reveals many
potential areas for future research.
It is likely that in the decades to come our current un-
derstanding of COPD will continue to change and
evolve just as it has during the past decade. Many differ-
ent areas of research as well as varied study designs will
be required to understand more completely this disease
that varies throughout a population and among individ-
uals during their life span. The current set of reviews
provides a framework for areas that are ripe for future
investigation as well as points out the challenges with
which clinical and translational research communities
are faced as we further our understanding of this com-
plex, common clinical entity.REFERENCES
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